Shionogi has been identifying in vitro activity using its antibiotic, cefiderocol, against Gram-negative clinical isolates such as carbapenem-resistant Enterobacterales (CRE). Christine Slover, PharmD, offers some insights on the company’s analysis.
Christine Slover PharmD
Advertisement
Executive Medical Director for Anti-Infectives at Shionogi Inc.
Articles by Christine Slover PharmD
Christine Slover, PharmD discussed cefiderocol's effectiveness against challenging infections, including those caused by multi-drug resistant bacteria.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Ethiopia Investigates Marburg Virus Disease Outbreak
2
World AIDS Day 2025: Global Setbacks and New Strategies to Sustain Progress Toward 2030 HIV Targets
3
HIV Drug Resistance Declines in the Modern ART Era
4
Scynexis Collaborates With Hackensack Meridian CDI, Johns Hopkins to Develop Therapeutics for Drug-Resistant Fungal Infections
5
